SCHEMBL4382960

SCHEMBL4382960

Cn1cncc1C(c1ccc(Cl)cc1)c1ccc(N)c(C(=O)c2cccc(Cl)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 4/20 0.52
FNTB P49356 4/20 0.52
ALOX15 P16050 1/20 0.39
S1PR2 O95136 2/20 0.36
S1PR4 O95977 2/20 0.36
S1PR3 Q99500 2/20 0.36
IDO1 P14902 1/20 0.36
FGFR1 P11362 1/20 0.36
FGFR2 P21802 1/20 0.36
FGFR3 P22607 1/20 0.36
ALDH1A1 P00352 2/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
PGGT1B P53609 1/20 0.35
AKT1 P31749 1/20 0.35
DYRK3 O43781 1/20 0.35
LIMK1 P53667 1/20 0.35
PIM3 Q86V86 1/20 0.35
PIM2 Q9P1W9 1/20 0.35
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5779400 0.79 CYP19A1 (0.54) ALOX15S1PR2S1PR4S1PR3ALDH1A1
SCHEMBL4381517 0.79 FNTA (0.50) FNTAFNTBIDO1PGGT1BMAPK1
SCHEMBL4381109 0.75 FNTA (0.54) FNTAFNTB
SCHEMBL4377478 0.75 FNTA (0.45) FNTAFNTBMAPK1
SCHEMBL4378944 0.74 FNTA (0.49) FNTAFNTBIDO1PGGT1B
SCHEMBL22726448 0.74 FNTA (0.35) FNTAFNTB
SCHEMBL6341269 0.72 RECQL (0.60) ALOX15ALDH1A1POLBMAPT
SCHEMBL5783128 0.71 FNTA (0.66) FNTAFNTBIDO1PGGT1B
SCHEMBL15201680 0.70 IDO1 (0.50) ALOX15IDO1ALDH1A1
SCHEMBL5549507 0.69 RORC (0.47) FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1339709-B1 FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2009-06-24 EP disclosed
US-7153958-B2 Farnesyl transferase inhibiting benzoheterocyclic derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-26 US disclosed
US-20040034218-A1 Farnesyl transferase inhibiting benzoheterocyclic derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2004-02-19 US disclosed
EP-1339709-A1 FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-09-03 EP disclosed
WO-2002042296-A1 FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034218-A1 Farnesyl transferase inhibiting benzoheterocyclic derivatives FNTA, FNTB, RCE1 FNTA 1/4885FNTB 2/4885ALOX15 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.